SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the ...
The aXess vascular access conduit. [Image from the Xeltis website] Xeltis today announced successful clinical data from a European trial of its aXess vascular access conduit in hemodialysis treatment.
A phase 2 trial of patients receiving hemodialysis via an arteriovenous graft found no benefit from a factor XI inhibitor. The monoclonal antibody MK-2060 does not meaningfully lower arteriovenous ...
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 ...
Pulmonary hypertension affects patients with hemodialysis-dependent end-stage kidney failure; however, the estimated prevalence varies greatly due to the underutilization of right heart ...
Introduction Decisions regarding the optimal vascular access for haemodialysis patients are becoming increasingly complex, and the provision of vascular access is open to variations in systems of care ...
Merit Medical Systems, Inc. MMSI recently announced the FDA's premarket approval for the WRAPSODY Cell-Impermeable Endoprosthesis. With this approval, MMSI can begin commercializing the device in the ...
Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial SOUTH JORDAN, Utah, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc.
ABSTRACT: Aim(s): Complex Arteriovenous fistula (AVF) poses challenges to cannulation. Ultrasound (US)-guided cannulation may promote successful cannulation and prevent AVF-related complications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results